Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 8/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NSD2 | O96028 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.43 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.43 |
| ▸ | BCL6 | P41182 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14768722 | 0.81 | KMT2A (0.44) | KDM4E | |
| SCHEMBL14768732 | 0.78 | KMT2A (0.51) | CCR4SMN1; SMN2POLBGAANSD2 | |
| SCHEMBL26111515 | 0.77 | PDE10A (0.40) | SMN1; SMN2KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL25366120 | 0.73 | PIK3CA (0.36) | ALDH1A1LMNA | |
| SCHEMBL27191077 | 0.72 | PDGFRB (0.51) | CCR4SMN1; SMN2POLBGAANSD2 | |
| SCHEMBL25016061 | 0.70 | BTK (0.45) | GAA | |
| SCHEMBL17122602 | 0.70 | EHMT2 (0.76) | CCR4SMN1; SMN2POLBGAANSD2 | |
| SCHEMBL15280231 | 0.70 | EHMT2 (0.76) | CCR4SMN1; SMN2POLBGAANSD2 | |
| SCHEMBL14768725 | 0.70 | KMT2A (0.45) | GAAKDM4EMAPT | |
| SCHEMBL27196854 | 0.70 | KMT2A (0.60) | CCR4SMN1; SMN2POLBGAANSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065883-A1 | Triazolo [4, 5- B] Pyridin Derivatives | Centro Nacional de Investigaceiones Oncologicas (CNIO) (ES) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065883-A1 | Triazolo [4, 5- B] Pyridin Derivatives | PIM1, PIM3, PIM2 | CCR4 3808/4885SMN1; SMN2 4123/4885POLB 1747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.